Video

Dr. Rohit Jain on factors affecting treatment selection in renal cell carcinoma

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).

Note: this interview was filmed before the FDA approval of pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.